- Shares of OraSure (OSUR +6%) rebound after Monday's big losses as Citi comes to the company's defense amid concerns that the FDA's warning to customer 23andMe could hit OSUR's top-line.
- Citi reminds investors that 23andMe accounts for less than 5% of OSUR's revenue.
- In response to the 23andMe controversy, OSUR is out reaffirming Q4 guidance: "This reaffirmation is being made after the company learned today that a customer of its molecular collection systems subsidiary, DNA Genotek, received a warning letter from the FDA," OSUR said.
- Q4 outlook: Consolidated net income of $0.07-0.08/share on revenue of $27.5-28M. (PR)
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Nasdaq.com (Thu, 4:27PM)
at Zacks.com (Thu, 8:46AM)
at Benzinga.com (Dec 31, 2014)
at CNBC.com (Nov 19, 2012)
at CNBC.com (Oct 23, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs